The person that worries me about Amarex is the CEO. He has over 30 years of experience in clinical research; clinical research activities with the National Institutes of Health (NIH); has presented to the U.S. FDA on more than 100 clinical products and to other regulatory agencies in both Europe and Asia. He has also participated in many DSMBs and has worked in a variety of therapeutic areas, including AIDS.

So here we have a guy who knows how effective Leronlimab is, he's an HIV expert, and has friends with competing drugs. I could see our numbers getting buried and calling it incompetence. And he probably has NP's trust to do a good job.